These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 17342038)

  • 1. Stent thrombosis in the era of drug eluting stents.
    Kawaguchi R; Angiolillo DJ; Futamatsu H; Suzuki N; Bass TA; Costa MA
    Minerva Cardioangiol; 2007 Apr; 55(2):199-211. PubMed ID: 17342038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Optimal platelet inhibition after coronary stent implantation. Current status].
    Silber S; Hoffmeister HM; Bode C
    Herz; 2008 Jun; 33(4):244-53. PubMed ID: 18581073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
    Marzocchi A; Saia F; Piovaccari G; Manari A; Aurier E; Benassi A; Cremonesi A; Percoco G; Varani E; Magnavacchi P; Guastaroba P; Grilli R; Maresta A
    Circulation; 2007 Jun; 115(25):3181-8. PubMed ID: 17562952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives.
    Jaffe R; Strauss BH
    J Am Coll Cardiol; 2007 Jul; 50(2):119-27. PubMed ID: 17616295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-eluting stent thrombosis.
    Steinberg DH; Satler LF
    Minerva Cardioangiol; 2008 Feb; 56(1):127-37. PubMed ID: 18432175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives.
    Ducrocq G; Serebruany V; Tanguay JF
    Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):939-53. PubMed ID: 17867923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Very late bare-metal stent thrombosis. A case report and review of the literature.
    Manjappa N; Agarwal A; Cavusoglu E
    J Invasive Cardiol; 2006 Jul; 18(7):E203-6. PubMed ID: 16816449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era.
    Rodriguez AE
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):561-76. PubMed ID: 19712016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-eluting stents and stent thrombosis: a cause for concern?
    Wernick MH; Jeremias A; Carrozza JP
    Coron Artery Dis; 2006 Dec; 17(8):661-5. PubMed ID: 17119373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive balloon postdilatation after stent deployment: is it still necessary with drug-eluting stents?
    Brodie BR
    J Interv Cardiol; 2006 Feb; 19(1):43-50. PubMed ID: 16483339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet therapy following drug-eluting stent implantation: new clinical data and recommendations.
    Paradis JM; Ducrocq G; Tanguay JF
    Minerva Cardioangiol; 2008 Feb; 56(1):139-54. PubMed ID: 18432176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stent thrombosis after percutaneous coronary intervention for bifurcation lesions.
    Tan HC
    J Interv Cardiol; 2009 Apr; 22(2):114-6. PubMed ID: 19379468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes after multilesion percutaneous coronary intervention: comparison between exclusive and selective use of drug-eluting stents.
    Bertrand OF; Faurie B; Larose E; Nguyen CM; Gleeton O; Déry JP; Noël B; Proulx G; Roy L; Costerousse O; De Larochellière R; Rodés-Cabau J
    J Invasive Cardiol; 2008 Mar; 20(3):99-104. PubMed ID: 18316823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent very late stent thrombosis after bare-metal stent implantation.
    Saito T; Asajima H
    Catheter Cardiovasc Interv; 2007 Jul; 70(1):51-3. PubMed ID: 17295327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Stent thrombosis in the era of drug-eluting stents].
    Wöhrle J
    Herz; 2007 Aug; 32(5):411-8. PubMed ID: 17687531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late stent thrombosis with drug-eluting stents: the price to pay to prevent restenosis?
    Kumbhani DJ; Bavry AA; Bhatt DL
    Indian Heart J; 2007; 59(2 Suppl B):B113-7. PubMed ID: 19153427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: a prospective single-center registry in high-risk patients.
    Miglionico M; Patti G; D'Ambrosio A; Di Sciascio G
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):600-4. PubMed ID: 18360849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The conundrum of late and very late stent thrombosis following drug-eluting stent implantation.
    Garg P; Mauri L
    Curr Opin Cardiol; 2007 Nov; 22(6):565-71. PubMed ID: 17921745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.